Ikaika Therapeutics jobs and careers

About Ikaika Therapeutics

Ikaika is expanding the frontier of fibrotic treatments through the power of genetics – Our team uncovered a novel target capable of modifying the outcome of fibrotic diseases. We identified genetic signals that regulate muscle disease progression by combining quantitative trait loci mapping with genome-wide mapping. We established that latent TGF-β binding protein 4 (LTBP4) has a key role in modulating fibrosis deposition, as LTBP4 inhibits activation of latent transforming growth factor-β (TGF-β), a well-known regulator that promotes fibrosis formation.